| 前收市價 | 5.14 |
| 開市 | 5.28 |
| 買盤 | 5.05 x 100 |
| 賣出價 | 5.09 x 200 |
| 今日波幅 | 5.05 - 5.31 |
| 52 週波幅 | 3.86 - 9.12 |
| 成交量 | |
| 平均成交量 | 756,019 |
| 市值 | 643.249M |
| Beta 值 (5 年，每月) | 0.78 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.50 |
| 業績公佈日 | 2024年5月20日 - 2024年5月24日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 8.67 |
InvestorPlaceThe Top 3 Healthcare Stocks to Buy on Weakness in 2024
Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ:NVDA). The sector is also getting a lift from the U.S. Federal Reserve’s decision to stop raising rates and its suggestions that it will cut rates later this year. Lower rates make it much easier for drug makers to obtain funds to finance the development of pharmaceuticals. Meanwhile, many pharmaceutical firms have rather low valuations because they dropped
- Reuters
Exscientia fires CEO after probe over relationship with two employees
British biotech Exscientia Plc said on Tuesday it had dismissed CEO Andrew Hopkins after an investigation found that his relationship with two employees was "inconsistent with the company's standards and values". Exscientia said a special committee of its board had engaged an outside counsel to look into Hopkins' conduct. The company said Chairman David Nicholson resigned from the board on Feb. 12 after it was discovered during the investigation that Nicholson had prior knowledge about one of Hopkins' relationships.
InvestorPlaceThe Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market. This could mark the beginning of a new era for some next-gen biotech stocks. Insilico Medicine is known as one of the first organizations to receive FDA approval for initial clinical tri
